EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Nanovaccine Based on Adjuvant Peptide FK‐13 and l ‐Phenylalanine Poly(ester amide) Enhances CD8 + T Cell‐Mediated Antitumor Immunity

Chunyuan Xie, Xinru You, Hongxia Zhang, Jiahui Li, Liying Wang, Yongxiang Liu, Zining Wang, Ruhui Yao, Tong Tong, Mengyun Li, Xiaojuan Wang, Lei Cui und 5 weitere

Advanced Science · 2023-07 · 10 (20)

DOI: 10.1002/advs.202300418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 10.05.2023. Verfasst von Chunyuan Xie und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Do…. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Guangdong Innovative and Entrepreneurial Research Team Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer vaccines have shown promise as effective means of antitumor immunotherapy by inducing tumor antigen‐specific T cell immunity. In this study, a novel peptide‐based tumor nanovaccine that boosts antigen presentation and elicits effective antitumor immunity is developed. The adjuvant characteristics of an antimicrobial peptide‐derived core peptide, FK‐13, are investigated and used it to generate a fusion peptide named FK‐33 with tumor antigen epitopes. l ‐phenylalanine‐based poly(ester amide) (Phe‐PEA), 8p4, is also identified as a competent delivery vehicle for the fusion peptide FK‐33. Notably, the vaccination of 8p4 + FK‐33 nanoparticles (8FNs) in vivo induces dendritic cell activation in the lymph nodes and elicits robust tumor antigen‐specific CD8 + T cell response. The nanovaccine 8FNs demonstrate significant therapeutic and prophylactic efficacy against in situ tumor growth, effectively inhibit tumor metastasis, and significantly prolong the survival of tumor‐bearing mice. Moreover, 8FNs can incorporate different tumor antigens and exhibit a synergistic therapeutic effect with antiprogrammed cell death protein 1 (PD‐1) therapy. In summary, 8FNs represent a promising platform for personalized cancer vaccines and may serve as a potential combinational modality to improve current immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsAnimalsMiceAmidesMice, Inbred C57BLPeptidesAdjuvants, ImmunologicCD8-Positive T-LymphocytesAntigens, Neoplasm

Stichwörter der Autor:innen

FK-13Phe-PEAadjuvantimmunotherapytumor nanovaccine

Substanzen

Cancer VaccinesAmidesPeptidesAdjuvants, ImmunologicAntigens, Neoplasm

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, China.
  • Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • School of Food Science and Technology, National Engineering Research Center of Seafood, Dalian Polytechnic University, Dalian, 116024, China.
  • School of Biomedical Engineering, Sun Yat-sen University, 66 Gongchang Road, Shenzhen, 518107, China.
  • State Key Laboratory of Biocontrol, School of Life Science, Sun Yat-sen University, 135 Xingang West Road, Guangzhou, 510275, China.
  • Bioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Nansha, Guangzhou, 511400, China.

ORCID-Profile: Jun Wu

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Guangdong Innovative and Entrepreneurial Research Team Program
  • International Cooperation and Exchange of the National Natural Science Foundation of China
  • Shenzhen Basic Research Project
  • Fundamental Research Funds for the Central Universities
  • China Postdoctoral Science Foundation
  • Guangdong Basic and Applied Basic Research Foundation

Zitieren

APA

Xie, C., You, X., Zhang, H., Li, J., Wang, L., Liu, Y., Wang, Z., Yao, R., Tong, T., Li, M., Wang, X., Cui, L., Zhang, H., Guo, H., Li, C., Wu, J., & Xia, X. (2023). A Nanovaccine Based on Adjuvant Peptide FK‐13 and l ‐Phenylalanine Poly(ester amide) Enhances CD8 + T Cell‐Mediated Antitumor Immunity. Advanced Science, 10(20). https://doi.org/10.1002/advs.202300418

Vancouver

Xie C, You X, Zhang H, Li J, Wang L, Liu Y, et al. A Nanovaccine Based on Adjuvant Peptide FK‐13 and l ‐Phenylalanine Poly(ester amide) Enhances CD8 + T Cell‐Mediated Antitumor Immunity. Advanced Science. 2023;10(20). doi:10.1002/advs.202300418

BibTeX
@article{Xie2023,
  author = {Xie, Chunyuan and You, Xinru and Zhang, Hongxia and Li, Jiahui and Wang, Liying and Liu, Yongxiang and Wang, Zining and Yao, Ruhui and Tong, Tong and Li, Mengyun and Wang, Xiaojuan and Cui, Lei and Zhang, Huanling and Guo, Hui and Li, Chunwei and Wu, Jun and Xia, Xiaojun},
  title = {A Nanovaccine Based on Adjuvant Peptide FK‐13 and l ‐Phenylalanine Poly(ester amide) Enhances CD8 + T Cell‐Mediated Antitumor Immunity},
  journal = {Advanced Science},
  year = {2023},
  volume = {10},
  number = {20},
  doi = {10.1002/advs.202300418}
}
Kostenlos starten →